L. Weeks, A. Niroula, D. Neuberg, W. Wong, R. C. Lindsley, M. Luskin, N. Berliner, R. Stone, D. DeAngelo, R. Soiffer, M. Uddin, G. Griffin, C. Vlasschaert, C. Gibson, S. Jaiswal, A. Bick, L. Malcovati, P. Natarajan, B. Ebert
2022.11.15BLOOD
tlooto Summary
The CHRS provides simple prognostic framework for CHIP/CCUS, distinguishing a high risk minority from the majority of CHIP/CCUS which has minimal risk for progression to MN.
Abstract
BACKGROUND Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cyto-penia of undetermined signi fi cance (CCUS) are de fi ned by somatic mutations in genes associated with myeloid neoplasms (MN) at a variant allele fraction (VAF) of 0.02 or greater in the absence and presence of cytopenia, respectively. CHIP/CCUS is highly prevalent in adults, and de fi ning predictors of MN risk would aid clinical management and research. METHODS We analyzed sequenced exomes of healthy U.K. Biobank participants (N 5 438,890)
Citation format
WEEKS, L., et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. BLOOD, 2022, 2.